Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.980
+0.010 (1.07%)
Nov 20, 2024, 4:00 PM EST - Market closed
Jaguar Health Revenue
Jaguar Health had revenue of $3.11M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $10.48M, down -2.25% year-over-year. In the year 2023, Jaguar Health had annual revenue of $9.76M, down -18.36%.
Revenue (ttm)
$10.48M
Revenue Growth
-2.25%
P/S Ratio
0.43
Revenue / Employee
$213,878
Employees
49
Market Cap
9.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 728.11M |
XWELL | 33.83M |
Mobile-health Network Solutions | 13.97M |
Vaccinex | 388.00K |
Soligenix | 364.18K |
FOXO Technologies | 155.00K |
Eyenovia | 31.83K |
JAGX News
- 1 day ago - Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” - Accesswire
- 5 days ago - Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Jaguar Health Reports Third Quarter 2024 Financial Results - Accesswire
- 9 days ago - Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Accesswire
- 14 days ago - FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - Accesswire
- 16 days ago - Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 22 days ago - Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting - Accesswire
- 5 weeks ago - Small-cap biotech Jaguar Health's stock jumps 7% as it launches treatment for oral mucositis in cancer patients - Market Watch